VLDL lipidomics reveals hepatocellular lipidome changes in metabolic dysfunction–associated steatotic liver disease
Hepatic steatosis and liver fibrosis in MASLD are associated with distinct VLDL-lipidomic signatures, respectively. This relationship is further modified by MASLD-genetics, suggesting a differential impact of pathogenic features on hepatocellular lipid homeostasis.
Authors
- Margery A. Connelly (ORCID: https://orcid.org/0000-0002-3917-592X)
- David Guardamino Ojeda (ORCID: https://orcid.org/0000-0002-3122-2218)
- Michelle Lai (ORCID: https://orcid.org/0000-0002-1035-0659)
- John M. Asara (ORCID: https://orcid.org/0000-0001-7450-2589)
- Susmita Bhattarai (ORCID: https://orcid.org/0000-0002-5667-3218)
- Melissa Miller (ORCID: https://orcid.org/0000-0002-8570-3981)
- Z. Gordon Jiang (ORCID: https://orcid.org/0000-0003-0495-9940)
- Yered Pita-Juárez (ORCID: https://orcid.org/0000-0001-6992-252X)
- Yusuf Yalcin (ORCID: https://orcid.org/0000-0001-5571-4842)
- Zsu‐Zsu Chen (ORCID: https://orcid.org/0000-0001-9441-675X)
- Aaron Hakim (ORCID: https://orcid.org/0000-0002-9752-8826)
Institutions
- Tufts University (US)
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Pfizer (United States) (US)
- LabCorp (United States) (US)
- Carney Hospital (US)
- David Yellin College of Education (IL)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1097/hc9.0000000000000716
- Citations
- 2
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.71